Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US requests marketing information from device, drug makers
Both Boston Scientific and Johnson & Johnson have been asked to provide information regarding drug-eluting stents, which are tubes that keep arteries open after they have been unclogged.
Both Boston Scientific and Johnson & Johnson have been asked to provide information regarding drug-eluting stents, which are tubes that keep arteries open after they have been unclogged.
The Food and Drug Administration issued the approval for Tekturna as the first in a new class of drugs called direct renin inhibitors. A once-daily oral therapy, Tekturna
Peramivir is a member of the class of antiviral agents that inhibit influenza viral neuraminidase, an enzyme that is essential for the spread of influenza virus within the
According to YM, unlike fixed dose approaches to opioid delivery, where a significant titration period is often required to determine the suitable dose for the patient, AeroLEF is
Although an independent data monitoring committee found that among the 826 patients, there was not a statistically significant difference between treatment groups in overall mortality. The phase III
Kathleen Hermans Messerschmidt, who filed suit on behalf of her brother, Brian Hermans, will not be able to continue the case against Merck into the second phase of
The agreement, following US Federal Trade Commission review, resolves litigation between Teva’s supplier of the 300 mg product, Impax Laboratories, and Biovail, involving a patent which expires in
The transaction has received approval from Hypnion stockholders and is expected to close near the end of the first quarter of 2007, subject to regulatory clearance. Financial terms
In the phase II trial, many patients with Alzheimer's disease got no worse over two full years, and in some cases, patients treated with Flurizan appear to have
The phase IIa trial evaluated the safety and efficacy of MEM 1003 for the treatment of acute mania in bipolar disorder. The primary outcome measure was at least